Antibiotic Treatment to Patients With Low Back Pain

NCT ID: NCT00302796

Last Updated: 2010-05-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

162 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Study Completion Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A large proportion of patients with Low Back Pain (LBP) (80 %) are classified as "non-specific", due to the lack of a patho-anatomical diagnosis. This term is not satisfactory, since it implies uncertainty for both the patient and the clinician. Modic changes have recently been identified as a pain giving patho-anatomical diagnosis for a considerable percentage (20-30 %) of LBP patients. The causes of these Modic changes have not been determined conclusively but bacterial infection is among the plausible causes for those following a disc herniation.

Purpose The aim of this study is to assess the clinical effect of antibiotic treatment compared to placebo, in patients with LBP and Modic changes following a lumbar herniated disc.

Design A double blind prospective clinically controlled trial. Patients will be randomized by a blinded observer to either Group A: 1 antibiotic tablet 45 patients Group B: 1 placebo tablet 36 patients Group C: 2 antibiotic tablets 45 patients Group D: 2 placebo tablets 36 patients

The patients will take the drug three times a day for 100 days.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Back Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A, Antibiotic

1 antibiotic tablet 45 patients Group

Group Type EXPERIMENTAL

Bioclavid

Intervention Type DRUG

500 + 125 mg times 3 or 6

Group B: 1 placebo

1 placebo tablet

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Group C: Antibiotics

2 antibiotic tablets 45 patients

Group Type EXPERIMENTAL

Bioclavid

Intervention Type DRUG

500 + 125 mg times 3 or 6

Group D, Placebo

2 placebo tablets 36 patients

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bioclavid

500 + 125 mg times 3 or 6

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18-65 years
* Previous lumbar herniated disc confirmed by MRI
* Time since lumbar disc herniation more than 6 months less than 2 years
* LBP in the area of L1 to L5, with an added Low Back Pain Rating Scale of 6 or more
* The present MRI shows Modic changes
* Positive Springing test (SPT) at the level of Modic changes

Exclusion Criteria

* Allergy against antibiotics
* The Beck Depression Inventory \>7,
* Pregnancy
* Breast feeding
* All Kidney diseases
* Pending workers litigation or pension
* Danish as second language
* Fertile women who do not user safe anti conseption
* Reduced liver functions
* Reduced liver function due to previous treatment wiht amoxicillin/clavulanasid.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Back Research Center, Denmark

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

The Back Research Center

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hanne B Albert, Ph.D

Role: PRINCIPAL_INVESTIGATOR

The Back Research Center, University of Southern Denmark

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Back Research Center

Ringe, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2005-005500-17

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Low Back Pain and Antibiotic Treatment
NCT00285493 WITHDRAWN PHASE1